International Stem Cell Corp (ISCO) 1.9700 $ISCO
International Stem Cell Corporation Announces Publication of Preclinical Results Demonstrating Treatment of Parkinson's Disease in Cell Transplantation
Marketwired - Thu Jun 02, 7:30AM CDT
CARLSBAD, CA--(Marketwired - June 02, 2016) - International Stem Cell Corporation (OTCQB: ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that it has published the results of a 12-month pre-clinical, non-human primate study. The data demonstrates the safety and efficacy of the company's proprietary ISC-hpNSC® readily expandable neural stem cell derived treatment of Parkinson's disease.
Cryoport to Provide Cold Chain Logistics Support for International Stem Cell Corporation's Phase I Clinical Trial for the Treatment of Parkinson's Disease
PR Newswire - Mon May 23, 7:00AM CDT
Cryoport, Inc. (NASDAQ: CYRX) ("Company"
, the world's leading cryogenic logistics company for the life sciences industry, today announced that it will provide global logistics support to International Stem Cell Corporation's (OTCQB: ISCO) ("ISCO" for its Phase I clinical trial in Australia for the treatment of moderate to severe Parkinson's disease. ISCO commenced patient enrollment for the study earlier this month.
CYRX: 1.82 (+0.04)
International Stem Cell Corporation Announces Operating Results for the Three-Months Ended March 31, 2016
Marketwired - Tue May 17, 7:31AM CDT
CARLSBAD, CA--(Marketwired - May 17, 2016) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company" , a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced operating results for the three months ended March 31, 2016.
International Stem Cell Corporation Announces 2015 Fourth Quarter and Year-End Results
Marketwired - Thu Mar 31, 7:31AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company" , a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced fourth quarter and year-end financial results for the period ended December 31, 2015.
International Stem Cell Corporation to Raise $6.3 Million Through a Private Placement to Fund Phase I Clinical Trial
Marketwired - Thu Mar 10, 7:30AM CST
International Stem Cell Corporation (OTCQB: ISCO), a clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products , announced today it has entered into definitive agreements with two institutional healthcare investors and management for the private placement of $6.3 million of the Company's convertible preferred stock and common stock purchase warrants to purchase up to an additional $25.7 million of the Company's common stock. The gross proceeds for the initial purchase of securities consisted of $2.5 million in cash and conversion of $3.8 million debt. Dr. Andrey Semechkin, the Company's Co-Chairman and Chief Executive Officer, purchased $4.3 million of the preferred stock (on the same terms as the outside investor) through conversion of the $3.8 million of indebtedness owed to him and $500,000 of cash. The closing of the offering is expected to occur on or about March 15, 2016, subject to satisfaction of customary closing conditions set forth in the Purchase Agreement.
International Stem Cell Corporation Announces Commencement of Enrollment of Phase I Trial of ISC-hpNSC
Marketwired - Mon Mar 07, 7:31AM CST
International Stem Cell Corporation (OTCQB: ISCO), a clinical stage biotechnology company developing novel stem cell-based therapies, announced today that it is enrolling patients in the Phase I trial of ISC-hpNSC®, human parthenogenetic stem cell-derived neural stem cells for the treatment of moderate to severe Parkinson's disease. The Melbourne Health Human Research Ethics Committee (HREC) granted its approval of the Phase I clinical trial in patients with moderate to severe Parkinson's disease. This approval clears the study's initiation at the Royal Melbourne Hospital. Parkinson's disease has no cure and is the second most common neurodegenerative disease affecting over 7 million people worldwide.
Retinitis Pigmentosa Pipeline Review, H2 2015 Featuring 27 Companies and Respective Drug Profiles
M2 - Fri Feb 05, 4:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pz5gtq/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Retinitis Pigmentosa Overview - Therapeutics Development - Pipeline Products for Retinitis Pigmentosa - Overview - Pipeline Products for Retinitis Pigmentosa - Comparative Analysis - Retinitis Pigmentosa - Therapeutics under Development by Companies - Retinitis Pigmentosa - Therapeutics under Investigation by Universities/Institutes - Retinitis Pigmentosa - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Retinitis Pigmentosa - Products under Development by Companies - Retinitis Pigmentosa - Products under Investigation by Universities/Institutes - Retinitis Pigmentosa - Companies Involved in Therapeutics Development - Acucela Inc. - Amarantus Bioscience Holdings, Inc. - Applied Genetic Technologies Corporation - Asklepios BioPharmaceutical, Inc. - Caladrius Biosciences, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - Genable Technologies Limited - Genethon - GenSight Biologics SA - Grupo Ferrer Internacional, S.A. - InFlectis BioScience - International Stem Cell Corporation - Isis Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Orphagen Pharmaceuticals, Inc. - QLT Inc. - RegenxBio Inc. - ReNeuron Group Plc - SanBio, Inc. - Sanofi - Shire Plc - Spark Therapeutics, Inc. - Sucampo Pharmaceuticals, Inc. - Sun Pharma Advanced Research Company Ltd. For more information visit http://www.researchandmarkets.com/research/pz5gtq/retinitis
OCAT: 8.47 (+0.01), QLTI: 1.43 (unch), ISIS: 57.56 (-0.28), ONCE: 55.43 (+1.38), SHPG: 188.21 (-1.31), SCMP: 11.49 (+0.10), GNST: (), CLBS: 0.57 (+0.03)
International Stem Cell Corporation Signed a Clinical Service Agreement With the Florey Institute of Neuroscience and Mental Health
Marketwire Canada - Wed Dec 23, 7:47AM CST
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a clinical stage biotechnology company developing novel stem cell-based therapies, announced today that it has entered into a master clinical research agreement with the Florey Institute of Neuroscience and Mental Health (Florey) to conduct Phase I/IIa clinical trial, dose escalation trial of human parthenogenetic stem cells-derived neural stem cells (ISC-hpNSC) in Parkinson's disease (PD) patients. The Florey is one of the world's leading brain research centers, employing the largest neuroscience research team in Australia.
International Stem Cell Corporation Receives Authorization to Initiate Phase I/IIa Clinical Trial of ISC-hpNSC for the Treatment of Parkinson's Disease
Marketwired - Mon Dec 14, 7:30AM CST
International Stem Cell Corporation (OTCQB: ISCO), a leader in using pluripotent stem cells in regenerative medicine, announced today that the Therapeutics Goods Administration (TGA) of Australia cleared a regulatory submission of ISCO's wholly owned subsidiary, Cyto Therapeutics, to initiate a Phase I/IIa clinical trial, dose escalation trial of human parthenogenetic stem cells-derived neural stem cells (ISC-hpNSC) in patients with moderate to severe Parkinson's disease (PD). Currently, there is no cure for PD, which is the second most common neurodegenerative disease and affects over 7 million people worldwide.
International Stem Cell Corporation Announces Launch Plans for New Nano-Compound Products
Marketwire Canada - Tue Dec 01, 7:30AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that its wholly-owned subsidiary Lifeline Skin Care, Inc. (Lifeline) will launch its next generation skin care product based on a breakthrough nano-compound technology in time for December holiday season.
International Stem Cell Corporation Announces Operating Results for the Three- and Nine-Months Ended September 30, 2015
Marketwired - Mon Nov 16, 7:31AM CST
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company" , a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced operating results for the three and nine months ended September 30, 2015.
International Stem Cell Corporation Moves Forward With Parkinson's Disease Clinical Trials in Australia
Marketwired - Tue Nov 03, 7:31AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that after a recent meeting with Australian Therapeutics Goods Administration (TGA) the Company's wholly owned subsidiary Cyto Therapeutics signed a Letter of Intent (LOI) with Royal Melbourne Hospital (Australia) to conduct phase I/IIa clinical trials of ISCO's proprietary human parthenogenetic neural stem cells (hPNSCs) for the treatment of Parkinson's Disease. Under this process, a full agreement will be signed after TGA and the HREC approve the clinical protocol for the phase I/IIa trials.
International Stem Cell Corporation Announces Publication of Preclinical Results Demonstrating Treatment of Parkinson's Disease in Cell Transplantation
Marketwired - Thu Jun 02, 7:30AM CDT
CARLSBAD, CA--(Marketwired - June 02, 2016) - International Stem Cell Corporation (OTCQB: ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that it has published the results of a 12-month pre-clinical, non-human primate study. The data demonstrates the safety and efficacy of the company's proprietary ISC-hpNSC® readily expandable neural stem cell derived treatment of Parkinson's disease.
Cryoport to Provide Cold Chain Logistics Support for International Stem Cell Corporation's Phase I Clinical Trial for the Treatment of Parkinson's Disease
PR Newswire - Mon May 23, 7:00AM CDT
Cryoport, Inc. (NASDAQ: CYRX) ("Company"
, the world's leading cryogenic logistics company for the life sciences industry, today announced that it will provide global logistics support to International Stem Cell Corporation's (OTCQB: ISCO) ("ISCO" for its Phase I clinical trial in Australia for the treatment of moderate to severe Parkinson's disease. ISCO commenced patient enrollment for the study earlier this month. CYRX: 1.82 (+0.04)
International Stem Cell Corporation Announces Operating Results for the Three-Months Ended March 31, 2016
Marketwired - Tue May 17, 7:31AM CDT
CARLSBAD, CA--(Marketwired - May 17, 2016) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"
, a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced operating results for the three months ended March 31, 2016. International Stem Cell Corporation Announces 2015 Fourth Quarter and Year-End Results
Marketwired - Thu Mar 31, 7:31AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"
, a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced fourth quarter and year-end financial results for the period ended December 31, 2015. International Stem Cell Corporation to Raise $6.3 Million Through a Private Placement to Fund Phase I Clinical Trial
Marketwired - Thu Mar 10, 7:30AM CST
International Stem Cell Corporation (OTCQB: ISCO), a clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products , announced today it has entered into definitive agreements with two institutional healthcare investors and management for the private placement of $6.3 million of the Company's convertible preferred stock and common stock purchase warrants to purchase up to an additional $25.7 million of the Company's common stock. The gross proceeds for the initial purchase of securities consisted of $2.5 million in cash and conversion of $3.8 million debt. Dr. Andrey Semechkin, the Company's Co-Chairman and Chief Executive Officer, purchased $4.3 million of the preferred stock (on the same terms as the outside investor) through conversion of the $3.8 million of indebtedness owed to him and $500,000 of cash. The closing of the offering is expected to occur on or about March 15, 2016, subject to satisfaction of customary closing conditions set forth in the Purchase Agreement.
International Stem Cell Corporation Announces Commencement of Enrollment of Phase I Trial of ISC-hpNSC
Marketwired - Mon Mar 07, 7:31AM CST
International Stem Cell Corporation (OTCQB: ISCO), a clinical stage biotechnology company developing novel stem cell-based therapies, announced today that it is enrolling patients in the Phase I trial of ISC-hpNSC®, human parthenogenetic stem cell-derived neural stem cells for the treatment of moderate to severe Parkinson's disease. The Melbourne Health Human Research Ethics Committee (HREC) granted its approval of the Phase I clinical trial in patients with moderate to severe Parkinson's disease. This approval clears the study's initiation at the Royal Melbourne Hospital. Parkinson's disease has no cure and is the second most common neurodegenerative disease affecting over 7 million people worldwide.
Retinitis Pigmentosa Pipeline Review, H2 2015 Featuring 27 Companies and Respective Drug Profiles
M2 - Fri Feb 05, 4:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pz5gtq/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Retinitis Pigmentosa Overview - Therapeutics Development - Pipeline Products for Retinitis Pigmentosa - Overview - Pipeline Products for Retinitis Pigmentosa - Comparative Analysis - Retinitis Pigmentosa - Therapeutics under Development by Companies - Retinitis Pigmentosa - Therapeutics under Investigation by Universities/Institutes - Retinitis Pigmentosa - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Retinitis Pigmentosa - Products under Development by Companies - Retinitis Pigmentosa - Products under Investigation by Universities/Institutes - Retinitis Pigmentosa - Companies Involved in Therapeutics Development - Acucela Inc. - Amarantus Bioscience Holdings, Inc. - Applied Genetic Technologies Corporation - Asklepios BioPharmaceutical, Inc. - Caladrius Biosciences, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - Genable Technologies Limited - Genethon - GenSight Biologics SA - Grupo Ferrer Internacional, S.A. - InFlectis BioScience - International Stem Cell Corporation - Isis Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Orphagen Pharmaceuticals, Inc. - QLT Inc. - RegenxBio Inc. - ReNeuron Group Plc - SanBio, Inc. - Sanofi - Shire Plc - Spark Therapeutics, Inc. - Sucampo Pharmaceuticals, Inc. - Sun Pharma Advanced Research Company Ltd. For more information visit http://www.researchandmarkets.com/research/pz5gtq/retinitis
OCAT: 8.47 (+0.01), QLTI: 1.43 (unch), ISIS: 57.56 (-0.28), ONCE: 55.43 (+1.38), SHPG: 188.21 (-1.31), SCMP: 11.49 (+0.10), GNST: (), CLBS: 0.57 (+0.03)
International Stem Cell Corporation Signed a Clinical Service Agreement With the Florey Institute of Neuroscience and Mental Health
Marketwire Canada - Wed Dec 23, 7:47AM CST
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a clinical stage biotechnology company developing novel stem cell-based therapies, announced today that it has entered into a master clinical research agreement with the Florey Institute of Neuroscience and Mental Health (Florey) to conduct Phase I/IIa clinical trial, dose escalation trial of human parthenogenetic stem cells-derived neural stem cells (ISC-hpNSC) in Parkinson's disease (PD) patients. The Florey is one of the world's leading brain research centers, employing the largest neuroscience research team in Australia.
International Stem Cell Corporation Receives Authorization to Initiate Phase I/IIa Clinical Trial of ISC-hpNSC for the Treatment of Parkinson's Disease
Marketwired - Mon Dec 14, 7:30AM CST
International Stem Cell Corporation (OTCQB: ISCO), a leader in using pluripotent stem cells in regenerative medicine, announced today that the Therapeutics Goods Administration (TGA) of Australia cleared a regulatory submission of ISCO's wholly owned subsidiary, Cyto Therapeutics, to initiate a Phase I/IIa clinical trial, dose escalation trial of human parthenogenetic stem cells-derived neural stem cells (ISC-hpNSC) in patients with moderate to severe Parkinson's disease (PD). Currently, there is no cure for PD, which is the second most common neurodegenerative disease and affects over 7 million people worldwide.
International Stem Cell Corporation Announces Launch Plans for New Nano-Compound Products
Marketwire Canada - Tue Dec 01, 7:30AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that its wholly-owned subsidiary Lifeline Skin Care, Inc. (Lifeline) will launch its next generation skin care product based on a breakthrough nano-compound technology in time for December holiday season.
International Stem Cell Corporation Announces Operating Results for the Three- and Nine-Months Ended September 30, 2015
Marketwired - Mon Nov 16, 7:31AM CST
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"
, a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced operating results for the three and nine months ended September 30, 2015. International Stem Cell Corporation Moves Forward With Parkinson's Disease Clinical Trials in Australia
Marketwired - Tue Nov 03, 7:31AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that after a recent meeting with Australian Therapeutics Goods Administration (TGA) the Company's wholly owned subsidiary Cyto Therapeutics signed a Letter of Intent (LOI) with Royal Melbourne Hospital (Australia) to conduct phase I/IIa clinical trials of ISCO's proprietary human parthenogenetic neural stem cells (hPNSCs) for the treatment of Parkinson's Disease. Under this process, a full agreement will be signed after TGA and the HREC approve the clinical protocol for the phase I/IIa trials.
